It’s time to pay attention to a new warning from the FDA: the Adderall shortage is getting worse.

Last week, the FDA confirmed a nationwide drug shortage that treats attention-deficit/hyperactivity disorders. The announcement came more than two months after some pharmacies reported that they had difficulties filling prescriptions.

The shortage is related to the immediate-release form of Adderall.

Adderall is a stimulant that manages ADHD symptoms and can cause physical withdrawal symptoms if suddenly ceased, so filling prescriptions promptly is essential for patient care. For those impacted by the shortage, the FDA suggested patients work with their doctors on the best treatment options, which for some could include switching to the extended-release formulation of the drug.

The FDA stated that it is “in frequent communication with all manufacturers of amphetamine mixed salts, and one of those companies, Teva, is experiencing ongoing intermittent manufacturing delays.” Teva is the largest manufacturer of Adderall in the US.

The shortage initially started with a labor shortage on its packaging line, but it has since been resolved, and Teva says that they expect “inventory recovery in the coming months.” But warns of “intermittent delays through the end of the year.”

One doctor told ABC that “Parents are panicked. Their children are being sent home from school or told they cannot come back if they are not on their meds.” Students trying to take the SATs, apply for college, and find themselves without their necessary medication are in a severe bind – and it’s not good news that the shortage could continue through January.